{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/opioid-dependence/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"37edcefe-2b9f-5ab8-a584-be9e268559ac","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 0ab4a48f-9239-4eca-8dba-c9adfb13b53c --><h2>Changes</h2><!-- end field 0ab4a48f-9239-4eca-8dba-c9adfb13b53c -->","summary":null,"htmlStringContent":"<!-- begin item 58fb30eb-decf-46dd-afbd-2e176f27a1fb --><!-- begin field eae53453-8d79-4207-9388-84c514746eb5 --><p><strong>October 2020 </strong>— minor update. Information on the prevalence of drug dependency in different ethnic groups has been clarified.</p><p><strong>September 2020</strong> — minor update. Drug interactions for buprenorphine have been updated in line with revised manufacturer's SPC. </p><p><strong>June to July 2019</strong> — reviewed. A literature search was conducted in June 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No major changes have been made to the recommendations in this topic, however some minor structural changes have been made.</p><!-- end field eae53453-8d79-4207-9388-84c514746eb5 --><!-- end item 58fb30eb-decf-46dd-afbd-2e176f27a1fb -->","topic":{"id":"ef534296-f504-5d3e-9b47-3c0f08322658","topicId":"1acd30d9-6aea-492b-a570-5fbeb05d49f5","topicName":"Opioid dependence","slug":"opioid-dependence","lastRevised":"Last revised in October 2020","chapters":[{"id":"7b9e0e1a-3aea-5219-a001-dfd22a786292","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a0179729-bb50-55a3-a1dc-ca3cbd473972","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e63e1346-068d-56e6-891b-85878800d361","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"37edcefe-2b9f-5ab8-a584-be9e268559ac","slug":"changes","fullItemName":"Changes"},{"id":"b53b49f5-e58d-5325-8fee-7f9fdc057646","slug":"update","fullItemName":"Update"}]},{"id":"242f440f-b9b5-51a4-9d43-3492e963e9af","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5766349b-04fe-548c-9de5-0ff28c7803b9","slug":"goals","fullItemName":"Goals"},{"id":"2ed8ffe3-15a2-5e49-b2ad-033e1a4b5f22","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"419add6c-5149-5bbf-9be1-8854fefbccc4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"01b28023-8c52-53e9-a23d-43bb73f67990","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e459f916-c763-56aa-9a4e-a3e6ef261b0f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3a96bc65-6eb3-5a1c-99c3-2530b6d352f4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b1fa8640-11da-554d-9d7a-12696b906136","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"28447573-cc1d-50d6-bea5-720f6d22e335","slug":"definition","fullItemName":"Definition"},{"id":"d7f47150-a2c5-57f9-88aa-5353f86fc58a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e594be8-c4df-5032-ad75-87ab56cb2c7e","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a7da5320-e6b9-59fc-8e5a-558ea4c298d9","slug":"complications","fullItemName":"Complications"}]},{"id":"e747d7e1-25ca-5f67-9d22-349d2b18eddd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ee9cab5c-4665-56a2-9005-028143cc8f59","slug":"suspecting-opioid-dependency","fullItemName":"Suspecting opioid dependency"},{"id":"20c15a53-634f-5cb4-a88a-7cb5115d810b","slug":"initial-investigations","fullItemName":"Initial investigations"}]},{"id":"f37505e6-dc82-5755-b700-7d1966f8c252","fullItemName":"Management","slug":"management","subChapters":[{"id":"75fe82a9-9ba2-541a-80be-cd0cf879bca3","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"d05968e4-f2be-5378-b462-0b129f5dc5e6","slug":"management","fullItemName":"Scenario: Management"},{"id":"00d16467-be2b-538d-8a7c-4d4045cabd6e","slug":"managing-special-circumstances","fullItemName":"Scenario: Managing special circumstances"}]},{"id":"0cf2cc09-9ca4-58a8-91c7-d64c38924b5a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ccbe88d0-314a-57fa-a61a-8a83bbfc9baf","slug":"writing-prescriptions-for-substitution-therapy","fullItemName":"Writing prescriptions for substitution therapy"},{"id":"5c859eeb-d8fd-50f5-8b18-e1a6a71ac111","slug":"methadone","fullItemName":"Methadone"},{"id":"3021db45-0a93-5ca8-a386-8d3e71abad63","slug":"buprenorphine","fullItemName":"Buprenorphine"}]},{"id":"9547692f-53b7-5f09-944d-6a4a6229dead","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0eafd778-db7f-578e-905f-1365ee1290a1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1d80b232-8932-503b-8765-30b929f15180","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"796c8942-47b7-56b5-a88a-cc0f133f5f3e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cfb530c5-aa05-5f4c-9e26-43caae839601","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"955b9fba-573b-57a0-b099-cf3356d6e837","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4f05fac2-c160-5e48-b55d-3898cce03ec0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0ead7d6b-f923-5852-bb7c-50aa97b9b2ff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e63e1346-068d-56e6-891b-85878800d361","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"26143dec-91c3-522a-b6fc-dd219b94df02","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 03295cde-6d13-4969-bf86-f09935da2a9d --><h3>Previous changes</h3><!-- end field 03295cde-6d13-4969-bf86-f09935da2a9d -->","summary":null,"htmlStringContent":"<!-- begin item bd0faeaa-d0a4-4021-8559-095fca17d113 --><!-- begin field 17b35f05-649f-4495-9609-b700d3e82cc6 --><p><strong>April 2017</strong> — revised. Updated structure, no changes have been made to the recommendations. </p><p><strong>April 2015</strong> — minor update. Update to the text to reflect the Driver and Vehicle Licensing Agency (DVLA) document <em>Drugs and driving: the law</em>.</p><p><strong>October 2013 to March 2014</strong> — reviewed. A literature search was conducted in October 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. New sections have been written on recovery-orientated drug treatment, the QTc interval, detection of drugs in the urine, and the management of acute and chronic pain. Minor changes have been made to the recommendations. Methadone is now recommended for detoxification from street heroin.</p><p><strong>September 2013</strong> — minor update to the text to reflect current recommendations regarding metoclopramide.</p><p><strong>July 2013</strong> — minor update. Links to the DVLA website have been updated.</p><p><strong>June 2012</strong> — minor update. Minor typographical error corrected.</p><p><strong>October 2011</strong> — minor update. Relevant recommendations from the NICE guideline <em>Needle and syringe programmes: providing people who inject drugs with injecting equipment</em> have been incorporated into this topic. Issued in December 2011.</p><p><strong>May 2011</strong> — minor update. Relevant recommendations from the NICE guideline <em>Psychosis with coexisting substance misuse</em> have been incorporated into this topic. Issued in June 2011.</p><p><strong>October 2010 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>October 2008</strong> — minor update to reflect changes in the Home Office <em>Application for personal import/export licence</em> form. Issued in October 2008.</p><p><strong>October 2007 to February 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>March 2007</strong> — minor update to include NICE technology appraisal guidance on methadone and buprenorphine and NICE technology appraisal guidance on naltrexone for the management of opioid dependence. Issued in March 2007.</p><p><strong>January to March 2006</strong> — reviewed. Validated in June 2006 and issued in July 2006. This guidance has been reviewed and updated following a full literature review. The guidance now incorporates recommendations from the Royal College of General Practitioners, the Royal Pharmaceutical Society of Great Britain and the National Treatment Agency. A more detailed evidence section to support the recommendations has been included.</p><p><strong>May 2003</strong> — updated to include the Royal College of General Practitioners' publication of <em>Guidance for the use of buprenorphine for the treatment of opioid dependence in primary care</em>. Validated in September and issued in February 2004.</p><p><strong>October 2002</strong> — rewritten and validated in March 2003.</p><p><strong>June 2001</strong> — updated to include the directive from the Chief Medical Officer and Chief Pharmaceutical Officer allowing the daily dispensing of buprenorphine for the management of drug dependence.</p><p><strong>May 1999</strong> — written.</p><!-- end field 17b35f05-649f-4495-9609-b700d3e82cc6 --><!-- end item bd0faeaa-d0a4-4021-8559-095fca17d113 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}